300,000 Californians Need New Driver's Licenses Thanks To A DMV Bug

Does dealing with the DMV give you a headache? Spare a thought for 300,000 Californian drivers, who now have invalid licenses ...

MannKind Provides Business Updates and 2026 Growth Drivers

MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through ...

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...

HER2-Positive Breast Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Roche Pharma AG, Dizal Pharma, …

In March 2025, The FDA awarded orphan drug designation to Nerlynx® (neratinib) for treating breast cancer patients with brain ...

EyePoint Pharmaceuticals, Inc.: EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 ...

Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra® (resmetirom) for ...